Mechanism and clinical implication of insulin resistance syndrome

Diabetes

Volumn 45, Issue 3 SUPPL., 1996, Pages

  Suzuki, Masaaki ^a   Ikebuchi, Motoyoshi ^a   Shinozaki, Kazuya ^a   Hara, Yasushi ^a   Tsushima, Motoo ^a   Matsuyama, Tatsuo ^a   Harano, Yutaka ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BENIDIPINE; BRANCHED CHAIN AMINO ACID; BUNAZOSIN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; GLUCOSE; NORADRENALIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTASSIUM;

AMINO ACID BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; BORDERLINE HYPERTENSION; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; ORAL GLUCOSE TOLERANCE TEST; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL;

ANGINA PECTORIS; ANTIHYPERTENSIVE AGENTS; ARTERIOSCLEROSIS; BLOOD PLATELETS; BODY WEIGHT; CALCIUM; CATECHOLAMINES; CORONARY DISEASE; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDINS; SYNDROME; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0029967247     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.45.3.s52     Document Type: Article

References (15)

1. Ginsberg H, Kimmerling G, Olefsky JM, Reaven GM: Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. J Clin Invest 55:454-461, 1975
2. Harano Y, Ogaku S, Kosugi K, Yasuda H, Nakano T, Kobayashi M, Hidaka H, Izumi K, Kashiwagi A, Shigeta Y: Clinical significance of altered insulin sensitivity in diabetes mellitus assessed by glucose, insulin, and somatostatin infusion. J Clin Endocrinol Metab 52:982-987, 1981
3. Ferrannini E, Buzzicoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilqacqua S: Insulin resistance in essential hypertension. N Engl J Med 317:350-357, 1987
4. Zuniga-Guajardo S, Jimenez J, Angel A, Zinman B: Effect of massive obesity on insulin sensitivity and insulin clearance and the metabolic response to insulin as assessed by the euglycemic clamp technique. Metabolism 35:278-282, 1986
5. Sheu WH-H, Shieh S-M, Full MM-T, Shen DD-C, Jeng C-Y, Chen Y-DI, Reaven GM: Insulin resistance, glucose intolerance, and hyperinsulinemia, hypertriglyceridemia versus hypercholesterolemia. Arterioscler Thromb 13:367-370, 1993
6. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
7. DeFronzo RA, Ferrannini E: Insulin resistance, a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
8. Harano Y, Kageyama A, Hirose J, Asakura Y, Yokota T, Ikebuchi M, Suzuki M, Omae T: Improvement of insulin sensitivity for glucose metabolism with long-acting Ca channel blocker, amlodipine in essential hypertensive subjects. Metabolism 44:315-319, 1995
9. Nohta H, Mitsui A, Ohkura Y: Spectrofluorimetric determination of catecholamines with 1,2-diphenylethylenediamine. Anal Chim Acta 165: 171-176, 1984
10. Declerck PJ, Alessi M-C, Verstreken M, Kruithof EKO, Julian-Vague I, Collen D: Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71:220-225, 1988
11. Ranby M, Nguyen G, Scarabin PY, Samama M: Immunoreactivity of tissue plasminogen activator and its inhibitor complexes, biochemical and multicenter validation of a two site immunosorbent assay. Thromb Haemostasis 61:409-414, 1989
12. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440-3450, 1985
13. World Health Organization: Definition, diagnosis, and classification. Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Sen, no. 727)
14. World Health Organization: Arterial Hypertension: Report of a WHO Expert Committee. Geneva, World Health Org., 1978 (Tech. Rep. Ser., no. 628
15. Suzuki M, Hirose J, Asakura Y, Sato A, Kageyama A, Harano Y, Omae T: Insulin insensitivity in nonobese, nondiabetic essential hypertension and its improvement by al blocker (bunazosin). Am J Hypertens 5:869-874, 1992